Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Amlodipine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1C known ✓ | Q13936 | 1/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 3/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 3/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 3/20 | 1.00 |
| ▸ | HTR1A | P08908 | 2/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 2/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 2/20 | 1.00 |
| ▸ | DRD1 | P21728 | 2/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 2/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 2/20 | 1.00 |
| ▸ | DRD3 | P35462 | 2/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
| ▸ | ABCB1 | P08183 | 2/20 | 1.00 |
| ▸ | ADRB3 | P13945 | 2/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 2/20 | 1.00 |
| ▸ | SCN5A | Q14524 | 2/20 | 1.00 |
| ▸ | KCNK2 | O95069 | 1/20 | 1.00 |
| ▸ | ADRB2 | P07550 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Amlodipine SCHEMBL912531 | 1.00 | TBXA2R (1.00) | TBXA2RADRA1ASLC6A3ADORA3ABCB11 | |
| Levamlodipine SCHEMBL30994756 | 1.00 | TBXA2R (1.00) | TBXA2RADRA1ASLC6A3ADORA3ABCB11 | |
| Amlodipine SCHEMBL7174865 | 1.00 | TBXA2R (1.00) | TBXA2RADRA1ASLC6A3ADORA3ABCB11 | |
| Amlodipine SCHEMBL29397019 | 1.00 | TBXA2R (1.00) | TBXA2RADRA1ASLC6A3ADORA3ABCB11 | |
| Amlodipine SCHEMBL1816641 | 1.00 | TBXA2R (1.00) | TBXA2RADRA1ASLC6A3ADORA3ABCB11 | |
| Amlodipine SCHEMBL26478 | 1.00 | TBXA2R (1.00) | TBXA2RADRA1ASLC6A3ADORA3ABCB11 | |
| Levamlodipine SCHEMBL41283 | 1.00 | TBXA2R (1.00) | TBXA2RADRA1ASLC6A3ADORA3ABCB11 | |
| SCHEMBL13097922 | 1.00 | TBXA2R (1.00) | TBXA2RADRA1ASLC6A3ADORA3ABCB11 | |
| SCHEMBL29599419 | 1.00 | TBXA2R (1.00) | TBXA2RADRA1ASLC6A3ADORA3ABCB11 | |
| Amlodipine SCHEMBL6666635 | 0.99 | TBXA2R (0.98) | TBXA2RADRA1ASLC6A3ADORA3ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4606374-A1 | PHARMACEUTICAL COMPOSITION COMPRISING AZILSARTAN MEDOXOMIL POTASSIUM AND CALCIUM CHANNEL BLOCKER, METHOD FOR PREPARING SAME, AND USE THEREOF | Shanghai Aurora Biotechnology Co., Ltd. (CN) | 2025-08-27 | — | — | EP | disclosed |
| EP-4588475-A1 | NEBIVOLOL AND AMLODIPINE COMPOSITION, PREPARATION METHOD THEREFOR, AND USE THEREOF | Shanghai Yonsun Biotechnology Co., Ltd. (CN) | 2025-07-23 | — | — | EP | disclosed |
| CN-112955965-B | Method for lowering blood pressure using dihydropyridine calcium channel blocker pharmaceutical compositions | 阿斯利康(英国)有限公司 | 2024-04-09 | — | — | CN | disclosed |
| EP-4114364-A1 | FORMULATION OF LISINOPRIL AND AMLODIPINE | Alkaloid AD Skopje (MK) | 2023-01-11 | — | — | EP | disclosed |
| EP-3236950-B1 | PHARMACEUTICAL COMPOSITION COMPRISING CANDESARTAN OR PHARMACEUTICALLY ACCEPTABLE SALTS OR ESTERS THEREOF AND AMLODIPINE OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | KRKA D D NOVO MESTO (SI) | 2022-11-23 | — | — | EP | disclosed |
| EP-4048273-A1 | NOVEL DRUG COMBINATIONS FOR TREATMENT OF A CARCINOMA | Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis (NL) | 2022-08-31 | — | — | EP | disclosed |
| CN-114728000-A | Novel pharmaceutical combination for the treatment of cancer | 荷兰癌症研究所-安东尼·范·雷文虎克医院基金会 | 2022-07-08 | — | — | CN | disclosed |